{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:17:46Z","timestamp":1792279066573,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,2]]},"DOI":"10.7759\/cureus.91467","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T12:40:46Z","timestamp":1756816846000},"source":"Crossref","is-referenced-by-count":1,"title":["Underutilization of Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction: A Retrospective Study in Rural Appalachia"],"prefix":"10.7759","author":[{"given":"Koushik","family":"Sanku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanskrita","family":"Nemalikanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwatobi","family":"Adegbile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeepthi","family":"Mekala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Vatsavayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Willey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghaith","family":"Husari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadii M","family":"Mamudu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata","family":"Vedantam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"79","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2022, 79:e263-421. 10.1016\/j.jacc.2021.12.012","journal-title":"J Am Coll Cardiol"},{"key":"ref2","unstructured":"2022 AHA\/ACC\/HFSA heart failure guideline. key perspectives. (2022). Accessed: 04\/01\/2022: https:\/\/www.acc.org\/Latest-in-Cardiology\/ten-points-to-remember\/2022\/03\/29\/19\/53\/2022-AHA-ACC-HFSA-Heart-Failure-Guid...."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry","volume":"72","author":"Greene SJ","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM, et al.. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry. J Am Coll Cardiol. 2018, 72:351-66. 10.1016\/j.jacc.2018.04.070","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2017.04.010","article-title":"Change the management of patients with heart failure: rationale and design of the CHAMP-HF registry","volume":"189","author":"DeVore AD","year":"2017","unstructured":"DeVore AD, Thomas L, Albert NM, et al.. Change the management of patients with heart failure: rationale and design of the CHAMP-HF registry. Am Heart J. 2017, 189:177-83. 10.1016\/j.ahj.2017.04.010","journal-title":"Am Heart J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","unstructured":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987, 316.1429-35. 10.1056\/NEJM198706043162301","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt B","year":"2000","unstructured":"Pitt B, Poole-Wilson PA, Segal R, et al.. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000, 355:1582-7. 10.1016\/s0140-6736(00)02213-3","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger CB","year":"2003","unstructured":"Granger CB, McMurray JJ, Yusuf S, et al.. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003, 362:772-6. 10.1016\/S0140-6736(03)14284-5","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105835","article-title":"Hyperkalemia with RAAS inhibition: mechanism, clinical significance, and management","volume":"172","author":"Hundemer GL","year":"2021","unstructured":"Hundemer GL, Sood MM. Hyperkalemia with RAAS inhibition: mechanism, clinical significance, and management. Pharmacol Res. 2021, 172:105835. 10.1016\/j.phrs.2021.105835","journal-title":"Pharmacol Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12821","article-title":"Blockade of the renin-angiotensin system and the risk of acute kidney injury","volume":"18","author":"Burnier M","year":"2016","unstructured":"Burnier M. Blockade of the renin-angiotensin system and the risk of acute kidney injury. J Clin Hypertens (Greenwich). 2016, 18:512-3. 10.1111\/jch.12821","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.054","article-title":"Arni-induced hypotension in HFrEF: a feared side-effect or a marker of modifiable risk?","volume":"84","author":"Al-Mohammad A","year":"2024","unstructured":"Al-Mohammad A. Arni-induced hypotension in HFrEF: a feared side-effect or a marker of modifiable risk?. J Am Coll Cardiol. 2024, 84:1701-3. 10.1016\/j.jacc.2024.08.054","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C286","article-title":"Extended-release metoprolol succinate in chronic heart failure","volume":"37","author":"Tangeman HJ","year":"2003","unstructured":"Tangeman HJ, Patterson JH. Extended-release metoprolol succinate in chronic heart failure. Ann Pharmacother. 2003, 37:701-10. 10.1345\/aph.1C286","journal-title":"Ann Pharmacother"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson PA","year":"2003","unstructured":"Poole-Wilson PA, Swedberg K, Cleland JG, et al.. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003, 362:7-13. 10.1016\/S0140-6736(03)13800-7","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer M","year":"2001","unstructured":"Packer M, Coats AJ, Fowler MB, et al.. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001, 344:1651-8. 10.1056\/NEJM200105313442201","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt B","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999, 341:709-17. 10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad F","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, et al.. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011, 364:11-21. 10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy CW","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al.. 2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2013, 128:1810-52. 10.1161\/CIR.0b013e31829e8807","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7133.2011.00250.x","article-title":"Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF","volume":"18","author":"Gheorghiade M","year":"2012","unstructured":"Gheorghiade M, Albert NM, Curtis AB, et al.. Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF. Congest Heart Fail. 2012, 18:9-17. 10.1111\/j.1751-7133.2011.00250.x","journal-title":"Congest Heart Fail"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.934471","article-title":"Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF)","volume":"122","author":"Fonarow GC","year":"2010","unstructured":"Fonarow GC, Albert NM, Curtis AB, et al.. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010, 122:585-96. 10.1161\/CIRCULATIONAHA.109.934471","journal-title":"Circulation"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.03.012","article-title":"Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"153","author":"Fonarow GC","year":"2007","unstructured":"Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2007, 153:1021-8. 10.1016\/j.ahj.2007.03.012","journal-title":"Am Heart J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.14.1493","article-title":"Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF)","volume":"167","author":"Fonarow GC","year":"2007","unstructured":"Fonarow GC, Abraham WT, Albert NM, et al.. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med. 2007, 167:1493-502. 10.1001\/archinte.167.14.1493","journal-title":"Arch Intern Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.773838","article-title":"Use of cardiac resynchronization therapy in patients hospitalized with heart failure","volume":"118","author":"Piccini JP","year":"2008","unstructured":"Piccini JP, Hernandez AF, Dai D, et al.. Use of cardiac resynchronization therapy in patients hospitalized with heart failure. Circulation. 2008, 118:926-33. 10.1161\/CIRCULATIONAHA.108.773838","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/401597-underutilization-of-guideline-directed-medical-therapy-in-heart-failure-with-reduced-ejection-fraction-a-retrospective-study-in-rural-appalachia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T12:40:48Z","timestamp":1756816848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/401597-underutilization-of-guideline-directed-medical-therapy-in-heart-failure-with-reduced-ejection-fraction-a-retrospective-study-in-rural-appalachia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.91467","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,2]]}}}